News_AntibodySystem

Home / Information / News

Information

Information Close

News

10
2026-09

2026 Lasker Awards: From Orexin to Parkinson's Disease

The 2026 Lasker Awards recognize discoveries in orexin signaling, bispecific antibody therapy, and Parkinson’s disease research advocacy. Explore the science behind this year’s awards.

More
07
2026-09

CD19 FMC63 scFv Research Reagents for CAR-T Cell Therapy

CD19 is a B-lineage-restricted surface antigen expressed on normal and malignant B cells, making it a widely explored target for immunotherapy, particularly CD19-directed CAR-T cell therapy. The FMC63 monoclonal antibody, a mouse IgG2a antibody specific for CD19, is one of the most widely used sources for generating CD19-targeting CAR antigen-binding domains. The FMC63-derived single-chain variable fragment (scFv) plays a critical role in antigen recognition and has been incorporated into numerous CD19 CAR-T constructs.

More
04
2026-09

Avian Influenza H5 Viruses Research Reagents

High-quality avian influenza H5 research reagents including recombinant HA, NA, M2e proteins and monoclonal/polyclonal antibodies for H5N1 and H5N6 subtypes. Validated for ELISA, WB, IHC, and neutralization assays. Accelerate your avian flu and vaccine research.

More
04
2026-09

Uruguay Reports Highly Pathogenic H5 Avian Influenza: New Challenges for H5 Virus Surveillance and Antibody Research

Uruguay has reported another case of highly pathogenic H5 avian influenza in 2026. As H5 viruses continue to evolve and spread across hosts, what does this mean for virus surveillance and antibody research?

More
02
2026-09

Influenza viruses Research Reagents

Comprehensive influenza research reagents including monoclonal antibodies, recombinant proteins, and ELISA kits targeting HA, NA, NP, M1, and more. Validated for ELISA, WB, IHC, and neutralization assays. Accelerate your flu and vaccine research.

More
02
2026-09

2026 New Zealand Influenza Outbreak: Influenza A Dominates, with RSV and Rhinovirus Activity Also Increasing

2026 New Zealand flu season driven by Influenza A (H3N2), with RSV and rhinovirus co-circulating. This article reviews influenza virus structure, HA/NA function, antigenic variation, and research tools from AntibodySystem

More
28
2026-08

Entacmaea quadricolor mTagBFP2 Research Reagents

High-quality recombinant protein and polyclonal antibody targeting Entacmaea quadricolor mTagBFP2, validated for ELISA, WB, IHC and more

More
24
2026-08

Salmonella Outbreak Investigation in the U.S.: Understanding Salmonella Pathogenesis and Key Research Targets

CDC investigates Salmonella outbreak. This article covers Salmonella pathogenesis, key research targets including surface antigens, adhesion, motility, cell wall biosynthesis, and phage-associated proteins. AntibodySystem offers antibodies and recombinant proteins for Salmonella research.

More
19
2026-08

South Sudan's Cholera Outbreak: What Makes Some Vibrio cholerae Strains Virulent?

South Sudan's 2026 cholera outbreak: 110,574 cases, 1,721 deaths. Explore the molecular basis of Vibrio cholerae virulence—serogroups, TCP, CTXΦ, cholera toxin ctxB, and more. AntibodySystem offers antibodies and proteins for cholera research

More
12
2026-08

AntibodySystem New Citations in July 2026

In July 2026, AntibodySystem products were cited in high-impact journals including iMeta, Science Advances, and npj Biofilms. This summary highlights 7 representative studies covering recurrent pregnancy loss, antithrombotic therapy, allergic inflammation, macrophage-based liver therapy, diabetic vascular complications, EV detection, and influenza immune evasion, showcasing the versatility of AntibodySystem reagents.

More
07
2026-08

Chandipura Virus (CHPV): Structure, Pathogenesis, and Therapeutic Landscape

A 2026 Chandipura virus (CHPV) outbreak in Gujarat, India, reported 184 suspected cases and 22 deaths, all in children under 15. This article reviews CHPV protein architecture (N/P/M/G/L), transmission, neuropathogenic mechanisms, diagnostics, and vaccine development. AntibodySystem offers recombinant proteins and antibodies for CHPV research.

More
06
2026-08

Eli Lilly's Tirzepatide Posts $27.7 Billion in First-Half 2026 Sales: How Dual GIPR/GLP-1R Agonism Outperforms Selective GLP-1R Agonism

Eli Lilly's tirzepatide generated $27.7B in H1 2026, outpacing semaglutide by over $10B. Its imbalanced receptor engagement and biased signaling drive superior glycemic and weight-loss efficacy. AntibodySystem offers antibodies, ELISA kits, and recombinant proteins for tirzepatide and semaglutide research.

More

Terms of sale Website terms of use Cookie policy Privacy

Copyright © 2026 AntibodySystem All Rights Reserved. All Products are for Research Use Only